DakoCytomation buys oncology test rights
This article was originally published in The Gray Sheet
Executive Summary
Human Genome Sciences sells DakoCytomation exclusive worldwide rights to develop and commercialize its pharmacogenomic diagnostic tests for detecting solid tumor and hematopoietic cancer cells, the firm reports March 31. The tests are based on trail receptor-R1 and -R2 proteins...